2010
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal Of Medicine 2010, 362: 1663-1674. PMID: 20445180, DOI: 10.1056/nejmoa0910496.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion failureEverolimus-eluting stentsMajor secondary end pointPrimary end pointSecondary end pointsEnd pointMyocardial infarctionIschemia-driven target lesion revascularizationRoutine follow-up angiographyTarget vessel myocardial infarctionComposite rateTarget lesion revascularizationClinical end pointsCoronary artery diseaseSubgroup of patientsFollow-up angiographyEverolimus-ElutingAngiographic findingsPrespecified subgroupsArtery diseaseCardiac deathStent thrombosisPatientsStents
2008
Angiographic Surrogate End Points in Drug-Eluting Stent Trials A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials
Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic Surrogate End Points in Drug-Eluting Stent Trials A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials. Journal Of The American College Of Cardiology 2008, 51: 23-32. PMID: 18174032, DOI: 10.1016/j.jacc.2007.07.084.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBare metal stentsAngiographic measuresTLR riskEnd pointDifferent drug-eluting stentsPrimary end pointRisk of TLRFollow-up angiographyLower revascularization ratesSurrogate end pointsIndividual patient dataSuitable surrogate markerDES trialsRevascularization ratesTLR rateClinical restenosisControlled TrialsFuture trialsStent implantationStent trialsSurrogate marker